Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the European Commission (EC) has approved the transfer of the marketing authorisation for Alprolix® (eftrenonacog alfa), a recombinant clotting factor therapy developed for the treatment of haemophilia B,  from Biogen[i] to Sobi, making Sobi the marketing authorisation holder (MAH) in the EU.

  • AstraZeneca has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez Pharmaceuticals Inc., for the rights to branded and authorised generic Toprol-XL (metoprolol succinate) in the US. Toprol-XL is a beta-blocker medicine for the control of hypertension (high blood pressure), angina (chest pain) and heart failure. It was first approved in the US in 1992.

  • This year's Nobel Laureate discovered and elucidated mechanisms underlying autophagy, a fundamental process for degrading and recycling cellular components.

    The word autophagy originates from the Greek words auto-, meaning "self", and phagein, meaning "to eat". Thus,autophagy denotes "self eating". This concept emerged during the 1960's, when researchers first observed that the cell could destroy its own contents by enclosing it in membranes, forming sack-like vesicles that were transported to a recycling compartment, called the lysosome, for degradation. Difficulties in studying the phenomenon meant that little was known until, in a series of brilliant experiments in the early 1990's, Yoshinori Ohsumi used baker's yeast to identify genes essential for autophagy. He then went on to elucidate the underlying mechanisms for autophagy in yeast and showed that similar sophisticated machinery is used in our cells.

  • Sanofi Pasteur, the vaccines global business unit of Sanofi, announced Dengvaxia® dengue vaccine has now received its 11th marketing approval, four of which granted from Regulatory Authorities recognized by the World Health Organization (WHO). To date the vaccine is approved in Mexico, The Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore.

  • Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. The merger of IMS Health, a leading global information and technology services company, and Quintiles, the world’s largest provider of product development and integrated healthcare services, creates a leading information and tech-enabled healthcare service provider with global scale and reach, and a full suite of end-to-end clinical and commercial offerings.

  • Tesaro, Inc., an oncology-focused biopharmaceutical company, and Zai Lab (Shanghai) Co.,Ltd., a biopharmaceutical company based in China, announced a collaboration to support the development and commercialization of niraparib for patients in China and the potential to advance two immuno-oncology programmes outside of China.This partnership reflects the commitment of both companies to develop novel therapeutic approaches for people living with cancer around the world.

    [adsense:336x280:8701650588]

  • Mylan NV announced the US launch of metformin hydrochloride extended-release tablets USP, 500 mg and 1000 mg, a generic version of Watson's Fortamet. Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Subscribe to Pharma News